DiaMedica Therapeutics Inc. Common Stock vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| DMAC | JNJ | |
|---|---|---|
| Market Cap | $370.47 million | $626.09 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | $-37,541,000 | $21.04 billion |
JNJ leads on 2 of 2 size & scale factors.
Valuation
| DMAC | JNJ | |
|---|---|---|
| P/E Ratio | — | 30.26 |
| Price / Book | 9.66 | 7.37 |
| Price / Sales | — | 6.39 |
JNJ leads on 1 of 1 valuation factors.
Profitability
| DMAC | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | -97.92% | 24.76% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| DMAC | JNJ | |
|---|---|---|
| Dividend Yield | — | 2.05% |
| Payout Ratio | — | 62.18 |
DMAC and JNJ split the dividend factors evenly.
Risk & Sentiment
| DMAC | JNJ | |
|---|---|---|
| Short Interest | 0.05% | 0.67% |
DMAC leads on 1 of 1 risk & sentiment factors.
Dig deeper: DMAC overview, DMAC financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.